Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

OncoImmunology

Volumn 6, Issue 1, 2017, Pages

  Pitt, Jonathan M ^a,b,c   Vétizou, Marie ^a,b,c   Boneca, Ivo Gomperts ^b,d   Lepage, Patricia ^e   Chamaillard, Mathias ^f   Zitvogel, Laurence ^a,b,c,g,h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT PASTEUR   (France)

^e UMR1319 MICALIS   (France)

^f UNIV LILLE   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h Center of Clinical Investigations in Biotherapies of Cancer   (France)

Author keywords

Anti CTLA 4; Bacteroides; Cancer; Ipilimumab; Microbiome; Microbiota; T cell

Indexed keywords

ANTIBIOTIC AGENT; CD11B ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; IPILIMUMAB; RNA 16S;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL MICROBIOME; BACTEROIDES; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; CLINICAL OUTCOME; COLITIS; DENDRITIC CELL; GENETIC MANIPULATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSTIMULATION; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; LAMINA PROPRIA; NONHUMAN; PYROSEQUENCING; SYMBIOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

EID: 85019259316     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1132137     Document Type: Article

References (9)

1. Eberl G. A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol. 2010; 3:450-60; PMID:20445502; http://dx.doi.org/10.1038/mi.2010.20
2. Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med. 2015; 7:271ps1; PMID:25609166; http://dx.doi.org/10.1126/scitranslmed.3010473
3. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http://dx.doi.org/10.1126/science.1240537
4. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342:967-70; PMID:24264989; http://dx.doi.org/10.1126/science.1240527
5. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350:1079-84; PMID:26541610; http://dx.doi.org/10.1126/science.aad1329
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
7. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006; 24:2283-9; PMID:16710025; http://dx.doi.org/10.1200/JCO.2005.04.5716
8. Dasgupta S, Erturk-Hasdemir D, Ochoa-Reparaz J, Reinecker HC, Kasper DL. Plasmacytoid dendritic cells mediate anti-inflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms. Cell Host Microbe 2014; 15:413-23; PMID:24721570; http://dx.doi.org/10.1016/j.chom.2014.03.006
9. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350:1084-9; PMID:26541606; http://dx.doi.org/10.1126/science.aac4255